阿司匹林、氯吡格雷和华法令三联抗栓方案在冠心病治疗中的应用  

The Application of Triple Antithrombotic Therapy Combined with Aspirin,Clopidogrel and Warfarin in Patients with Coronary Heart Disease

作　　者：唐伟良[1,2] 彭放[1,2] 王兴祥[3] 郭航远[1,2] 

机构地区：[1]绍兴市人民医院 [2]浙江大学绍兴医院,浙江省绍兴市312000 [3]浙江大学医学院附属第一医院心血管内科,浙江省杭州市310029

出　　处：《中国动脉硬化杂志》2012年第10期956-960,共5页Chinese Journal of Arteriosclerosis

摘　　要：冠心病支架植入术后患者常规需要接受阿司匹林、氯吡格雷的双联抗血小板治疗,而当上述患者同时存在心房颤动、左心室血栓等抗凝治疗指征时,常常需要选择阿司匹林、氯吡格雷和华法令的三联抗栓治疗方案。然而,该治疗方案常伴随着显著的出血风险,其安全性、有效性、必要性等问题长期困扰着临床医师,也是当前研究者争论的一大热点问题。文章通过复习近年来的文献报道,对三联抗栓治疗在冠心病患者中的应用作一综述。The patients after coronary stent implantation requires regular dual antiplatelet therapy with aspirin and clopidogrel. When these patients are complicated with indications for anticoagulation therapy, such as atrial fibrillation, left ventrieular thrombosis and so on, the triple antithrombotic therapy combined with aspirin, c]opidogrel and warfarin is u- sually employed. However, because of significant bleeding risk of this treatment, clinicians are puzzled with its safety, effectiveness and necessity, and researchers currently debate this as a hot spot. In this paper, we have reviewed the re- cent literatures about the triple antithrombotic therapy, and discussed the application of this treatment in patients with coro- nary heart disease.

关 键 词：阿司匹林 氯吡格雷 华法令 三联抗栓治疗 冠心病 

分 类 号：R5[医药卫生—内科学]